While the rise in heart ailments across India is a growing concern, it has also triggered an unprecedented boom in the cardiovascular drug market. Over the past five years, demand for cardiac medications—including cholesterol-lowering drugs and heart failure therapies—has surged dramatically, with total sales reaching a staggering ₹30,483 crore in the 12 months ending April 2025.
According to data provided by market tracker PharmaTrac for The Economic Times, this marks a nearly 50% increase in cardiac drug sales compared to five years ago. Among the most consumed are lipid-lowering drugs and heart failure therapies, whose usage has almost doubled, reflecting the country’s increasing burden of lifestyle-related diseases such as obesity, diabetes, and hypertension.
This trend underscores both the urgent need for better preventive care and the growing reliance on long-term cardiovascular medications as a mainstay of treatment. As India grapples with rising cases of heart disease, the pharmaceutical industry is witnessing a parallel surge in business—one that reflects the critical intersection of public health and market dynamics.
Discussion about this post